A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 3103 participants.
Also called NCT07000123
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,103 participants
- Sponsor
- Registry
-
NCT07000123 -
2025-520521-21
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Czechia, Germany, Hungary, India, Japan, Malaysia, Poland, Slovakia, South Korea, Spain, Taiwan, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07000123. Randomized; triple masking; primary purpose treatment. Start 2025-05-28 (actual); primary completion 2027-01-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
- Acronym
- AZURE-LDL
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- AZD0780
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07000123- Content hash
f3e40100301be87fa69bc53ee7ed5c4965162a0fa52326634c614fbc09b91f05